CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Novel developments in revascularization for left main coronary artery disease Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Tissue characterisation of atherosclerotic plaque in the left main: an in vivo intravascular ultrasound radiofrequency data analysis Poor R-wave progression as a predictor of sudden cardiac death in general population and subjects with coronary artery disease The spectrum of heart failure: value of left ventricular ejection fraction and its moving trajectories Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study Diuretic Therapy for Patients With Heart Failure JACC State-of-the-Art Review

Original ResearchVolume 72, Issue 19, November 2018

JOURNAL:J Am Coll Cardiol. Article Link

Cardiorespiratory Fitness and Mortality in Healthy Men and Women

MT Imboden, MP Harber, MH Whaley et al. Keywords: cancer mortality; cardiovascular disease; exercise testing; physical fitness

ABSTRACT


BACKGROUND - There is a well-established inverse relationship between cardiorespiratory fitness (CRF) and mortality. However, this relationship has almost exclusively been studied using estimated CRF.

 

OBJECTIVES - This study aimed to assess the association of directly measured CRF, obtained using cardiopulmonary exercise (CPX) testing with all-cause, cardiovascular disease (CVD), and cancer mortality in apparently healthy men and women.

 

METHODS - Participants included 4,137 self-referred apparently healthy adults (2,326 men, 1,811 women; mean age: 42.8 ± 12.2 years) who underwent CPX testing to determine baseline CRF. Participants were followed for 24.2 ± 11.7 years (1.1 to 49.3 years) for mortality. Cox-proportional hazard models were performed to determine the relationship of CRF (ml·kg-1·min-1) and CRF level (low, moderate, and high) with mortality outcomes.

 

RESULTS - During follow-up, 727 participants died (524 men, 203 women). CPX-derived CRF was inversely related to all-cause, CVD, and cancer mortality. Low CRF was associated with higher risk for all-cause (hazard ratio [HR]: 1.73; 95% confidence interval [CI]: 1.20 to 3.50), CVD (HR: 2.27; 95% CI: 1.20 to 3.49), and cancer (HR: 2.07; 95% CI: 1.18 to 3.36) mortality compared with high CRF. Further, each metabolic equivalent increment increase in CRF was associated with a 11.6%, 16.1%, and 14.0% reductions in all-cause, CVD, and cancer mortality, respectively.

 

CONCLUSIONS - Given the prognostic ability of CPX-derived CRF for all-cause and disease-specific mortality outcomes, its use should be highly considered for apparently healthy populations as it may help to improve the efficacy of the individualized patient risk assessment and guide clinical decisions.